REGINfo: Biogen Idec Inc - Biotechnologie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

S&P 100 NEWS

> Accenture PLC

> Adobe Systems Inc

> Allstate Corp.

> Altria Group, Inc.

> Amazon.com Inc

> American Express

> American International Group

> Bank of America

> Bank of New York Mellon Corp

> Berkshire Hathaway Inc.

> Biogen Idec Inc

> Booking Holdings

> Bristol-Myers Squibb Co.

> Caterpillar Inc.

> Charter Communication

> Cisco Systems Inc

> Coca Cola Co.

> Colgate-Palmolive

> ConocoPhillips

> Costco Wholesale Corp

> CVS Caremark Corp.

> Eli Lilly & Co.

> Emerson Electric Co.

> Exelon Corporation

> Exxon Mobil Corp.

> Ford Motor Company

> General Dynamics

> General Electric

> General Motors

> Gilead Sciences Inc

> Goldman Sachs Group, Inc.

> Home Depot, Inc

> Honeywell International, Inc.

> International Business Machines (IBM)

> Johnson & Johnson

> JP Morgan Chase & Co

> Kinder Morgan Inc

> Lockheed Martin

> Lowes Companies

> Mastercard Inc A

> McDonald's Corp.

> Medtronic, Inc.

> Merck & Co., Inc.

> Mondelez International Inc

> Morgan Stanley

> NextEra Energy Inc

> Occidental Petroleum

> ...

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Biogen Idec Inc: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2020.09.14 | 13:30 | Permanent Information Releases / General Company News

puce Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health - HTML (w)

2020.09.11 | 14:01 | Permanent Information Releases / General Company News

puce New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio - HTML (w)

2020.09.08 | 13:30 | Permanent Information Releases / General Company News

puce New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS - HTML (w)

2020.08.07 | 13:30 | Permanent Information Releases / General Company News

puce FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review - HTML (w)

2020.08.06 | 14:02 | Permanent Information Releases / General Company News

puce Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases - HTML (w)

2020.07.24 | 22:06 | Permanent Information Releases / General Company News

puce Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease - HTML (w)

2020.07.22 | Permanent Information Releases / Appointments

puce Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer - HTML (w)

2020.07.21 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec) - HTML (w)

2020.07.08 | 23:01 | Permanent Information Releases / Sales and Revenues

puce The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS - HTML (w)

2020.07.08 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease - HTML (w)

2020.06.10 | 13:30 | Permanent Information Releases / General Company News

puce New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment - HTML (w)

2020.06.04 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020 - HTML (w)

2020.05.28 | 13:30 | Permanent Information Releases / General Company News

puce Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science - HTML (w)

2020.05.19 | 13:30 | Permanent Information Releases / General Company News

puce New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS - HTML (w)

2020.05.18 | 13:30 | Permanent Information Releases / General Company News

puce New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 / Doc nb : 107